In the present study, our data suggest that UC-MSCs inhibited the proliferation of CD4+T cells and immunosuppressed the production of IL-22 in ITP patients through soluble cellular factors. The gene discussed is CD4; the disease is autoimmune thrombocytopenic purpura.